Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial.

By W. Atkin, R. Edwards, I. Kralj-Hans, K. Wooldrage, Andrew Hart, J. Northover, J. Wardle, S. W. Duffy, Jack Cuzick. The Lancet, 2010

1,669 citations recorded by the source corpus.

Subfields: Oncology

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Circulating Exosomal microRNAs as Biomarkers of Colon Cancer (2014, background): “Implementation of the fecal occult blood test and flexible sigmoidoscopy as screening methods has reduced CRC mortality [2,3].”
ACG Clinical Guidelines: Colorectal Cancer Screening 2021. (2021, background): “Two trials, fromtheUnitedKingdom(Flexi Scope trial) and Italy (SCORE), offered once-only flexible sigmoidoscopy examination toparticipants age55–64years and reporteda reduction in CRC incidence by 23% and 18% and CRC mortality by 31% and 22%, respectively (56,57).”
Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial--SCORE. (2011, methodology): “2 years) largely explain the observed differences in the estimates of screening effect in the intention-to-treat analysis, with a lower reduction of overall (18% vs 23%) and distal (24% vs 36%) CRC incidence in the SCORE trial vs the UK trial (13).”
Global cancer statistics (2011, background): “trial in the United Kingdom, a one-time flexible sigmoid-oscopy screening between 55 and 64 years of age reduced colorectal cancer incidence by 33% and mortality by 43%.(45)”